Minoryx MIN-102 trial

Minoryx Therapeutics have completed patient randomisation in its MIN-102 trial for patients with AMN, months earlier than expected.
“The strong interest in this AMN trial in the EU and US has resulted in exceeding the target enrolment ahead of schedule,” said Dr. Uwe Meya, chief medical officer of Minoryx. “We believe this highlights the very high unmet medical need in this area.”
Read the biospace article to find out more here